DYP688

PreclinicalSmall molecule

Novartis

DYP688 is one of 5 small molecule programs targeting Metastatic Uveal Melanoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Uveal MelanomaActive, not recruiting

Metastatic Uveal MelanomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Metastatic Uveal Melanoma

#DrugCompanyPhaseTrials

Zolinza

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 2

GM-CSF

YY-mAbs Therapeutics

Preclinical

1 3

Bcnu

GGeneral Oncology, Inc.

Preclinical

1 4

Tebentafusp-Tebn

TThomas Jefferson University

Preclinical

1 5

DYP688

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalActive, not recruiting

Metastatic Uveal Melanoma

NCT05415072

Clinical

Trials by Indication[1]

Metastatic Uveal Melanoma1 trial

A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas

Active, not recruiting· Novartis logo

Novartis·Preclinical·NCT05415072·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DYP688. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DYP688 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DYP688. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Novartis

DYP688

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Metastatic Uveal Melanoma1 trial

References

Drug Info

Quick Facts

Related News